Patients With Advanced Hr Positive News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dr Gradishar discusses the FDA approval of capivasertib plus fulvestrant for patients with advanced HR-positive, HER2-negative breast cancer harboring PIK3CA, AKT1, or PTEN alterations.

United statesWilliamj gradisharAshling wahnerNorthwestern university feinberg school of medicineDepartment of medicineLive on airBetsy bramsen professorBreast oncologyNorthwestern university feinberg schoolOnclive on airApple podcastsGoogle podcastsAmazon musicFda approval of capivasertib plus fulvestrantPatients with advanced hr positiveEr2 negative breast cancer harboring pik3ca